Harpoon Therapeutics Inc
:HARP 4:00:00 PM EDT
| Market Cap (Intraday) | NA |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $22.95 |
| 50-Day MA | $21.41 |
| 200-Day MA | $10.99 |
Harpoon Therapeutics Inc Stock, :HARP
611 Gateway Boulevard, Suite 400, South San Francisco, California 94080
United States of America
Phone: +1.650.443.7400
Number of Employees:
Description
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body�s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.